Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 7 de 7
Filtrar
Mais filtros










Intervalo de ano de publicação
1.
Int J Lepr Other Mycobact Dis ; 58(2): 296-301, 1990 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-2115904

RESUMO

The epidemiometric model of leprosy, built on Polambakkam, India, data, is used to compare the impact on incidence of dapsone and different multidrug therapy (MDT) strategies. The simulations show that generalization of MDT could have a dramatic impact on transmission of the disease. Relapses after MDT, although important from an individual point of view, have a negligible influence on the incidence. Introduction of MDT requires investments that, during the first few years of the program, are much greater than for dapsone monotherapy. These are, however, rapidly absorbed due to the rapidly declining number of new cases, particularly when MDT is not limited to multibacillary cases but is administered to all patients.


Assuntos
Simulação por Computador , Dapsona/uso terapêutico , Hansenostáticos/uso terapêutico , Hanseníase/tratamento farmacológico , Análise Custo-Benefício , Quimioterapia Combinada , Humanos , Incidência , Hanseníase/epidemiologia
2.
Int J Lepr Other Mycobact Dis ; 57(3): 599-606, 1989 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-2778367

RESUMO

Of the 47,068 patients registered in the Polambakkam Leprosy Center between 1955 and 1982, we selected 1886 cases having shown bacteriological positivity at any time during this period, whatever their classifications at registration, and subsequently found bacteriologically negative. After an average follow-up period of 10 years, 243 relapses were observed, giving a crude relapse rate of 12.8 per person-years of observation and a cumulative probability of relapse of 18.9%. Relapse rates were found to be dependent on regularity during smear-positive and -negative periods; a regularity greater than 75% in the smear-positive period proved to be particularly important. The results show no evidence that relapses occurring after 3 years of negativity could be reinfections, and that the relapse rate was still affected by regularity 7 years after negativation. The median delay of relapses was found to be 4.4 years and was not affected by the regularity of treatment.


Assuntos
Dapsona/uso terapêutico , Hanseníase/epidemiologia , Humanos , Hanseníase/tratamento farmacológico , Recidiva , Estudos Retrospectivos , Fatores de Tempo
4.
s.l; s.n; 1987. 7 p. tab.
Não convencional em Inglês | Sec. Est. Saúde SP, HANSEN, Hanseníase, SESSP-ILSLACERVO, Sec. Est. Saúde SP | ID: biblio-1231490
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...